SSTR2 and small cell carcinoma: SSTR2 expression in TET, specifically lymphoepithelial carcinomas, squamous cell carcinomas, atypical carcinoid tumors, and small cell carcinomas may be a biomarker to identify patients who may respond to octreotide therapy.